Bionomics' Victory - Analysts Note Optimism Around Promising Prospects for PTSD Treatment
Portfolio Pulse from Vandana Singh
Bionomics Limited (NASDAQ:BNOX) announced positive results from its Phase 2b ATTUNE trial of BNC210 for post-traumatic stress disorder (PTSD). The trial met its primary endpoint, leading to an upgrade of the stock from Neutral to Buy by HC Wainwright with a price target of $8. The company is now focusing on discussions with the FDA for the next phases of the PTSD program. Despite concerns about potential liver issues, the absence of observed liver injury is reassuring.
September 28, 2023 | 6:22 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Positive trial results and an upgrade from HC Wainwright could boost Bionomics' stock in the short term.
The positive results from the Phase 2b trial of BNC210 for PTSD and the subsequent upgrade of the stock by HC Wainwright are likely to have a positive impact on Bionomics' stock. The company's focus on discussions with the FDA for the next phases of the PTSD program also adds to the positive outlook.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100